Cepi.net
Italy pledges first EUR 5 million funding to CEPI to advance COVID-19 vaccine development efforts – CEPI
Financial contribution is part of a larger donation to support CEPI’s work.
Two more laboratories join CEPI’s centralised network to standardise assessment of COVID-19 vaccines – CEPI
The NIBSC and Q2 Solutions will work alongside five other laboratories, using the same testing reagents and following common protocols, for uniform evaluation and direct comparisons of COVID-19 vaccine candidates.
USA joins CEPI to support the development of epidemic vaccines – CEPI
A total of US$20 million will be provided to CEPI through USAID to support programmes advancing vaccines against emerging infectious diseases
CEPI expands global manufacturing network, reserving manufacturing capacity for more than 1 billion doses of COVID-19 vaccines – CEPI
CEPI has signed agreements with Biofabri (Spain) and GC Pharma (Republic of Korea) to reserve vaccine manufacturing capacity for more than 1 billion doses of COVID-19 vaccines designated by CEPI.
Private sector companies provide financial support for CEPI’s COVID-19 vaccine programmes – CEPI
Donations from companies including Nestlé, Beiersdorf, and Sumitomo Mitsui Financial Group, Inc. (SMFG), will help advance the development of CEPI-funded COVID-19 vaccine candidates.
Why we need a “portfolio approach” to COVID-19 vaccine development – CEPI
Hundreds of vaccine candidates against COVID-19 are under development. Predicting which of these will be successful is extremely difficult. That’s why we need multiple shots at goal, writes Nick Jackson, Head of Programmes and Innovative Technology...
CEPI establishes global network of laboratories to centralise assessment of COVID-19 vaccine candidates – CEPI
All COVID-19 vaccine developers can use the network of five laboratories working together as part of centralised network to reliably assess and compare immunological responses generated by COVID-19 vaccine candidates
Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility – CEPI
64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days
COVAX: A Moment of Truth in the Pandemic – CEPI
To succeed, COVAX requires broad international buy-in, based on the recognition that no one is safe until everyone is.
321 vaccine candidates against COVID-19 now in development – CEPI
CEPI report analyses the global progress that has been made in the search for a COVID-19 vaccine
Stevanato Group signs an agreement with CEPI to provide pharma glass vials for 2 billion doses of COVID-19 vaccines under development – CEPI
This supply is part of CEPI’s efforts to rapidly speed up the vaccine development timeline through making progress on manufacturing in parallel with the clinical development of COVID-19 candidate vaccines.
172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility – CEPI
172 economies are now engaged in discussions to potentially participate in COVAX, with the goal of bringing the pandemic under control via equitable access to COVID-19 vaccines.
How to measure the success of a COVID-19 vaccine? – CEPI
Dr Melanie Saville, CEPI’s Director of Vaccine Development, discusses what a successful vaccine against COVID-19 would involve, some of the unknowns and the challenges that vaccine developers are wrestling with, and what makes CEPI’s approach...
CEPI reserves manufacturing capacity for COVID-19 vaccines at SK bioscience – CEPI
CEPI has reserved vaccine manufacturing capacity at SK bioscience in 2020 and 2021 which will support the COVAX goal to produce 2 billion doses of safe and effective vaccine by the end of 2021.
CEPI-funded COVID-19 vaccine candidates progress to clinical trials – CEPI
Clover Biopharmaceuticals have started Phase 1 trials of its COVID-19 candidate vaccine. CureVac and the University of Queensland are also set to begin clinical trials shortly.